Search All
- Articles
- Books & Media
- Journals
- Databases
- Databases by Subject
- Frequently Asked Questions
- Our Website
Articles
-
Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus 1993
https://ncsu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fi9QwEB7cg8MDET0V63maB193t23SNsUnOW_xRRDuDnwLSZusK7ttvV5P9793Jm2XW3-A-FIG-ovkSzrzNd9MAN7YhIs0yc00tMhNMCKIaJGwoJ84ojSZK7XQ-z9z-qSwdpBVVoVZzar1ZlatvnhtZbMp5qNObP7p4xm5mTiZT2CS8XRk6MPKAdIbMVYIx8n8eVTvxHL-9XY1SzO0Z6kk0iRjTsl6_AgOpYgiLsWec5o4Xd8pG4wmbWilvfmg0S32oes3v_hTdPq7yPJ-VzV6-12v13c82OIRPBxCT_aub-JjuGerYzjsN6PcPoHL8x-DKLZitWP2W4cBKENIG9verq67lkVsud4WtS_tsKrYe2a2jHTzS6YZEeuN8bIaZnTRrWt_z1O4Wpxfnn2YDnsuTAtkQjdTk4bk4qUzpcZYAoOBqCiFDG2e-Ur2OjR54pDX5o6-ldw6mxdZUiKxcWgY_hyYQFSczksZ5kaE1klnQ2614L74e5gEEI29rJq-pobyXCSWCjFSaYa2IozowBVhFMAxwqH0Ej996uoiF5ySYAM4GeFRut38cncAb0fEdu9BR6FKdOKNohVnZ7goszguMOjFhvJcmIxTPZ0s0QGc7oG8ewSnbOQ0D-D1CLrCKUnrLLqyddeqKEWHjy39-xUkREJqIwN41g-S3cOHgRhAujd6duepGvj-GZwkvip4PykCiHfD7J8798X_vu0EjrwA1OdmvoSDm-vOnsIBZZ-88tOSjheLn-BMN2E
Journal Of Virology, Vol. 67, Issue 11, pp. 6820 - 6823.
Glycoprotein D (gD) of equine herpesvirus I (EHV-1) was expressed at the surface of insect cells infected by a recombinant baculovirus. ERV-1 gD was detected as multiple forms (56, 52, and 48 kDa) ... Read more
Glycoprotein D (gD) of equine herpesvirus I (EHV-1) was expressed at the surface of insect cells infected by a recombinant baculovirus. ERV-1 gD was detected as multiple forms (56, 52, and 48 kDa) from 18 to 96 h postinfection. Laboratory animals inoculated with the recombinant ERV-1 gD developed neutralizing antibody responses against both ERV-1 and ERV-4 Read less
Journal Article | Full Text Online
-
Preterm birth: Case definition & guidelines for data collection, analysis, and presentation... 2016
https://ncsu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwELdYKwZfeBQEhTEZCe1Ty5zEThz4NApVJzSoRjVNaJLlJDYrmrKqD6b-99w5LwpDPKTKqpucndpn-y7-3c-EvDAi4KGIkz4z4JuAReDhJmGKL3F4lkQ201xvvswhrIqF-XkL30GxvukUd5kRiBU6SlIutkgbFhfGW6R9cPh-9KGBdQTuMA9wLXife-y0idq5vqDfrUfbeHqVns7NdabnrwjKW6t8ptdX-uKiwFG65Wl4l5xVf8yhUvAshB_h-fuOEtHxYFT0j__SCPfIndJspQeFnt0nN0zeITeLgyzXHbJ9VG7Rd8jeuCDDXvfopIntWvToHh03NNkg0zlBJI4LB6aV-ANyNZ47gA5NpvPl-Ss6gFWWZsZOc4ctg1K-rJCZC9H6FAxuihBXitrsMGV5j-qSZgW_ZXTWhFfl9NLSqYuHKSBMdKGtWa5dEQ_JZPhuMhj1y8Mh-qmQnugnJk4xaDcLdZbKwGZcpmGSJCz1DPS9ZSKDuUqnEZOxDaRJQRnBeQOD1U9BInhMKI-C0Oo4kyxOODNWWsMCo3ngSOqZ6JKXlWqoWcH9oSpQ3FdV9ofC_lAsUNAfXRJVCqSqwFaYis2inBcWylMLXzH1iTk7lJ16yHgGTmuXyFqyNH0Kk0aBIvyp0teVqtZPiUIZ6NdMhT7ztY6EFWCqJD60g4wgr8M48biNoOKdSrtV85RglMLHk3GXPK8vw7yDm0k6N5crvEegdekx1iWPisFQV--DTxGEXEJ7bAyT-gbkNN-8kk_PHbe5AI9EMpDcrwfU37X9k_9vwafkNuYKkNIOaS3nK_OMtHCQ7pKt6PgE09PIpW8glQNvt5x2IDd8C7-1R4PD4WfIHbFjl04w9T9iGo2_A_nghcA
Vaccine, Vol. 34, Issue 49, pp. 6047 - 6056.
Abstract Preterm birth is commonly defined as any birth before 37 weeks completed weeks of gestation. An estimated 15 million infants are born preterm globally, disproportionately affecting low and... Read more
Abstract Preterm birth is commonly defined as any birth before 37 weeks completed weeks of gestation. An estimated 15 million infants are born preterm globally, disproportionately affecting low and middle income countries (LMIC). It contributes directly to estimated one million neonatal deaths annually and is a significant contributor to childhood morbidity. However, in many clinical settings, the information available to calculate completed weeks of gestation varies widely. Accurate dating of the last menstrual period (LMP), as well as access to clinical and ultrasonographic evaluation are important components of gestational age assessment antenatally. This case definition assign levels of confidence to categorisation of births as preterm, utilising assessment modalities which may be available across different settings. These are designed to enable systematic safety evaluation of vaccine clinical trials and post-implementation programmes of immunisations in pregnancy. Read less
Journal Article | Full Text Online
-
INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel... 2016
https://ncsu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_ePYgv4hdaPc8ogiD0tk3SNhVf1uMO7-FO0VN8C0manAvXdunuKv51_mvOpB9Q8cmXwtLZJHQyyW8mM78Q8tJlXORZaeLEgW8CiCDFQ0KLQRxRmcJXWuh5MIdkYy1MSNq3ZnXUXNdHzep7yK1c13Yx5oktPp4fA4bhgvPFHtkreD666MPRQSETORxfpjJfbGABlpiflsdMZvBA-t-iyEuWitleNK7IeGuVXnXuX5Dz78zJnlcqbEWnd8jtAUPSZT_Wu-SGa-6Rm-fDKfl98vvs4uLD1-XlyRu6pND6WE1J8TbcbksDpSz8qE24HYLCLNzVVDcVxdC77n5RLMrHvJ1uQzFQS5v2h7umeJnKDqNr8c8QUHUVrfVVg2WQFLz2Frk7HF3V4eIjCmiYArqEAeDAUP-hCzsxRPcFoLT1YYwIeqnFFroH5MvpyeXx-3i4qCG2gJe2cVYJJ5znjGeOSeNLaaRn0unElqwyqZbMGgCSsPOBB1VmLvMys1VZlC5lpmD8EaECNOl1WcmkNCJxXnqXcKcFD4zxSRaR16Ou1Lon4lDBgZG56nWsMFkNdaxYRJ6hNlVfSzoZsVrCtoBsPmkakRdBAikwGsyxudK7zUadff40E3o1CPkW1G31ULLQNg5Zs2aSBzNJsFE7e_12nFbT4Nf1qlIV4Im18s7A9wnOt8uTwjhkVTS2DMeWjgtofZyKalhiNgrW4iwFtJgXEXk-vcaOMW2uce2ulwGALUoekYf9zJ36H40gIsVsTk8CSDw-fwP2GAjIB_t7_N__fEJuMbRIwAAsPSD7227nnpJ9rFo5BJv-VoTnu8MQITkM9v0Hx1tUrQ
Bmc Cancer, Vol. 16, Issue 1, p. 816.
Whilst multi-parametric magnetic resonance imaging (mp-MRI) has been a significant advance in the diagnosis of prostate cancer, scanning all patients with elevated prostate specific antigen (PSA) l... Read more
Whilst multi-parametric magnetic resonance imaging (mp-MRI) has been a significant advance in the diagnosis of prostate cancer, scanning all patients with elevated prostate specific antigen (PSA) levels is considered too costly for widespread National Health Service (NHS) use, as the predictive value of PSA levels for significant disease is poor. Despite the fact that novel blood and urine tests are available which may predict aggressive disease better than PSA, they are not routinely employed due to a lack of clinical validity studies. Furthermore approximately 40 % of mp-MRI studies are reported as indeterminate, which can lead to repeat examinations or unnecessary biopsy with associated patient anxiety, discomfort, risk and additional costs. We aim to clinically validate a panel of minimally invasive promising blood and urine biomarkers, to better select patients that will benefit from a multiparametric prostate MRI. We will then test whether the performance of the mp-MRI can be improved by the addition of an advanced diffusion-weighted MRI technique, which uses a biophysical model to characterise tissue microstructure called VERDICT; Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours. INNOVATE is a prospective single centre cohort study in 365 patients. mp-MRI will act as the reference standard for the biomarker panel. A clinical outcome based reference standard based on biopsy, mp-MRI and follow-up will be used for VERDICT MRI. We expect the combined effect of biomarkers and VERDICT MRI will improve care by better detecting aggressive prostate cancer early and make mp-MRI before biopsy economically viable for universal NHS adoption. INNOVATE is registered on ClinicalTrials.gov, with reference NCT02689271 . Read less
Journal Article | Full Text Online
Books & Media
-
Pro HTML5 programming
https://catalog.lib.ncsu.edu/catalog/NCSU2653703
Online Resources QA76.76 .H94 L83 2011 ebook | Book
-
-
China : contemporary political, economic, and international affairs
https://catalog.lib.ncsu.edu/catalog/NCSU1998442
Hill DS779.26 .C47346 2007 | Book
Get Help
We didn't find any staff who match your query, but know that we're here to help.
Ask Us (chat, text, email)